Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Takeda Pharmaceutical Company Limited American Depositary Shares (each
(NY:
TAK
)
17.08
+0.39 (+2.34%)
Streaming Delayed Price
Updated: 10:08 AM EST, Jan 29, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Takeda Reports Strong First Quarter FY2023 Results, Driven by Growth & Launch Products
July 27, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
The New England Journal of Medicine Publishes Data from Phase 2 Study of First Oral Orexin Receptor 2 Agonist TAK-994 in Patients with Narcolepsy Type 1
July 26, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
(TAK) - Analyzing Takeda Pharmaceutical's Short Interest
↗
July 14, 2023
Via
Benzinga
Disney Considers Different Strategies For Star India, Broadcom Wins Conditional European Approval For VMware Deal, Google Deprioritizes Gen Z Chatbot App: Today's Top Stories
↗
July 12, 2023
Wall Street Journal
Via
Benzinga
Takeda Withdraws FDA Application For Dengue Vaccine Candidate On Data Disagreement
↗
July 12, 2023
Takeda Pharmaceutical Co Ltd (NYSE: TAK) said on Tuesday that it was voluntarily
Via
Benzinga
Week In Review: Billion Dollar Deals - Moderna’s Shanghai Investment And F-Star’s Takeda Collaboration
↗
July 08, 2023
F-star Therapeutics formed a license agreement with Takeda to develop Fcab domains aimed at undisclosed immuno-oncology targets. Also, Brii Bio signed a global license to an HBV immunotherapeutic...
Via
Talk Markets
Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK-755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
June 25, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
ADHD Medication Shortage Worsens, Vyvanse Supply Dwindles Amid Adderall Scarcity
↗
June 21, 2023
The supply of an alternative to Adderall, Vyvanse (lisdexamfetamine), a commonly used medication for Attention-deficit/hyperactivity disorder (ADHD), is dwindling, further limiting options for patients...
Via
Benzinga
Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis
↗
June 21, 2023
The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult...
Via
Benzinga
Takeda Presents Full Data Set from Phase 3 ADVANCE-CIDP 1 Clinical Trial Investigating HYQVIA® as a Maintenance Therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting
June 20, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
3 AI Stocks That Could Skyrocket Your Wealth
↗
June 20, 2023
AI is poised to greatly increase the top and bottom lines of many companies, making many AI stocks very attractive at this point.
Via
InvestorPlace
HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
June 15, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet
June 15, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
June 15, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Seagen's Adcetris/Immunotherapy Combo Achieves 98% Overall Response Rate in Early-Stage Lymphoma Setting
↗
June 13, 2023
Seagen Inc (NASDAQ: SGEN) announced updated efficacy and safety results from Part C of phase 2 single-arm trial of Adcetris (brentuximab vedotin) combined with nivolumab and standard chemotherapy...
Via
Benzinga
3 Stocks That Could Skyrocket by This Time Next Summer
↗
June 08, 2023
The best stocks to skyrocket in June have all done well in 2023 and over the past year. They definitely ought to be on your watchlist.
Via
InvestorPlace
Why Shares of Innate Pharma Jumped Thursday
↗
June 08, 2023
The company's collaboration agreement with Sanofi could soon pay off.
Via
The Motley Fool
Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress
May 26, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
May 25, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
FDA Approves First Oral Treatment For Crohn's Disease, Making Seventh Approval For AbbVie's Rinvoq
↗
May 19, 2023
The FDA approved AbbVie Inc's (NASDAQ: ABBV) Rinvoq (upadacitinib) for moderately to severely active Crohn's disease patients with inadequate response or intolerance to
Via
Benzinga
U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
May 16, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Moves Out From Licensing Agreement With Theravance Biopharma
↗
May 11, 2023
In its Q1 earnings release, Takeda Pharmaceutical Co Ltd (NYSE: TAK) said it agreed to discontinue further development of TAK-954 for post-operative gastrointestinal dysfunction and the parties'...
Via
Benzinga
Earnings Scheduled For May 11, 2023
↗
May 11, 2023
Companies Reporting Before The Bell • Takeda Pharmaceutical (NYSE:TAK) is likely to report earnings for its fourth quarter. • Exela Technologies (NASDAQ:XELA) is expected to report earnings for its...
Via
Benzinga
Takeda's FY22 Net Profit Jumps 38%, But Expects Lower FY23 Revenues
↗
May 11, 2023
Takeda Pharmaceutical Co Ltd's (NYSE: TAK) FY22 net profit rose 37.8% to ¥317.02 billion, mainly due to solid growth in its
Via
Benzinga
Takeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook
May 11, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
April 27, 2023
From
Takeda Pharmaceutical Company Limited
Via
Business Wire
Corza Medical Signs Definitive Agreement to Acquire Takeda's TachoSil Manufacturing Operations
April 26, 2023
From
Corza Medical Inc.
Via
GlobeNewswire
Cannabis Movers & Shakers: Latest Appointments From Khiron, MariMed, Equilibria & More
↗
April 25, 2023
Equilibria Strengthens Women's Wellness With New CSO
Via
Benzinga
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
↗
April 25, 2023
The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.
Via
The Motley Fool
This Supercharged Dividend King Stock Might Soon Run Out of Steam
↗
April 25, 2023
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
19
20
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
